aTyr Pharma, Inc. (ATYR : NASDAQ)
Common Stock
$0.13
USD
+0.00 (3.55%)
Last updated: 2026-10-28
Follow ATYR
ATYR
aTyr Pharma, Inc.
WealthAwesomePerformance
1 Day
+4041.94%
1 Week
+2880.85%
1 Month
+1625.23%
YTD
+1009.29%
Key Statistics
Market Cap
$12.90M
52W High
$5.20
52W Low
$0.15
P/E Ratio
-
50 Day MA
$13.80
200 Day MA
$24.33
Beta
0.91
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/28/2026 | $0.12 | $0.13 | $0.12 | $0.13 | $5.14 | 84,232 |
| 10/27/2026 | $0.12 | $0.13 | $0.10 | $0.12 | $0.12 | 8,186,373 |
| 10/26/2026 | $0.17 | $0.17 | $0.14 | $0.15 | $0.15 | 2,990,847 |
| 10/23/2026 | $0.17 | $0.17 | $0.16 | $0.17 | $0.17 | 1,295,600 |
| 10/22/2026 | $0.17 | $0.18 | $0.17 | $0.17 | $0.17 | 1,039,984 |
| 10/21/2026 | $0.17 | $0.18 | $0.17 | $0.17 | $0.17 | 1,212,552 |
| 10/20/2026 | $0.17 | $0.18 | $0.17 | $0.17 | $0.17 | 1,271,021 |
| 10/19/2026 | $0.18 | $0.18 | $0.17 | $0.17 | $0.17 | 2,099,810 |
| 10/16/2026 | $0.19 | $0.19 | $0.17 | $0.17 | $0.17 | 1,809,100 |
| 10/15/2026 | $0.19 | $0.20 | $0.18 | $0.18 | $0.18 | 2,223,734 |
Analyst Price Targets
Based on 9 analysts covering ATYR · as of Oct 29, 2026
Wall Street analysts forecast ATYR stock price to rise 88907.5% over the next 12 months.
Consensus
Buy3.67 / 5.00
Avg. Target
US$114.29
+88907.5% Upside
Previously US$2.86 on Oct 5, 2026
Current Price
US$0.13
Last close
Analyst Breakdown (9 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ATYR's historical volatility
30-Day Vol
1093.9%
Annualized
90-Day Vol
634.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$6.14
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$5.45 | US$0.13 – US$237.47 |
| 60 trading days | US$5.79 | US$0.03 – US$1203.43 |
| 90 trading days | US$6.14 | US$0.01 – US$4238.89 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company develops ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders; and develops and tests ATYR2810, the Company's monoclonal antibody that targets the neuropilin-2 (NRP2) receptor for the treatment of aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Financials
- Revenue (TTM)
- $190,000
- EBITDA
- $-63.20M
- Profit Margin
- 0.00%
- ROE (TTM)
- -98.68%
- EPS (Diluted)
- -26.06
- Book Value
- 0.50
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About ATYR.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| AXG | Solowin Holdings | $5.68 | +14100.00% |
| OMEX | Odyssey Marine Exploration Inc | $13.55 | +2418.59% |
| HVII | Hennessy Capital Investment Corp. VII Ordinary Shares | $4.46 | +243.08% |
| ULBI | Ultralife Corporation | $15.61 | +145.44% |
| ATII | Archimedes Tech SPAC Partners II Co. Ordinary Shares | $9.81 | +110.06% |
| RITRF | Reitar Logtech Holdings Limited | $0.02 | +86.09% |
| KPTI | Karyopharm Therapeutics Inc | $0.83 | +73.35% |
| FTFT | Future Fintech Group Inc | $2.89 | +55.38% |